AR105938A1 - Anticuerpo anti-epha4 - Google Patents
Anticuerpo anti-epha4Info
- Publication number
- AR105938A1 AR105938A1 ARP160102725A ARP160102725A AR105938A1 AR 105938 A1 AR105938 A1 AR 105938A1 AR P160102725 A ARP160102725 A AR P160102725A AR P160102725 A ARP160102725 A AR P160102725A AR 105938 A1 AR105938 A1 AR 105938A1
- Authority
- AR
- Argentina
- Prior art keywords
- epha4
- seq
- cdr
- amino acid
- acid sequence
- Prior art date
Links
- 102000021727 EphA4 Receptor Human genes 0.000 abstract 6
- 108010055179 EphA4 Receptor Proteins 0.000 abstract 6
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 3
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se entiende que proporciona un anticuerpo anti-EphA4 o un fragmento de unión a EphA4 de este que es capaz de unirse a EphA4 e inhibir la unión entre EphA4 y su ligando, y una composición farmacéutica que comprende el anticuerpo anti-EphA4 o el fragmento de unión a EphA4 de este como un ingrediente activo. Se obtuvo un anticuerpo anti-EphA4 de ratón que tiene afinidad de unión por EphA4 y se identificaron las secuencias de las regiones determinantes de complementariedad (CDR) del anticuerpo anti-EphA4 de ratón. Esto permitió la preparación de un anticuerpo humanizado que comprende las secuencias de CDR del anticuerpo anti-EphA4 de ratón en las regiones variables de la cadena pesada y cadena liviana. Reivindicación 1: Un anticuerpo anti-EphA4 o un fragmento de unión a EphA4 de este, que comprende (a) CDR-H1 que comprende la secuencia de aminoácidos representada por la SEQ ID Nº 26 o SEQ ID Nº 27; (b) CDR-H2 que comprende la secuencia de aminoácidos representada por la SEQ ID Nº 28 o SEQ ID Nº 29; (c) CDR-H3 que comprende la secuencia de aminoácidos representada por la SEQ ID Nº 30; (d) CDR-L1 que comprende la secuencia de aminoácidos representada por la SEQ ID Nº 31; (e) CDR-L2 que comprende la secuencia de aminoácidos representada por la SEQ ID Nº 32; y (f) CDR-L3 que comprende la secuencia de aminoácidos representada por la SEQ ID Nº 33.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015177081 | 2015-09-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR105938A1 true AR105938A1 (es) | 2017-11-22 |
Family
ID=58240770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160102725A AR105938A1 (es) | 2015-09-08 | 2016-09-06 | Anticuerpo anti-epha4 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10428140B2 (es) |
| EP (1) | EP3381941B1 (es) |
| JP (2) | JP6738814B2 (es) |
| KR (1) | KR20180041136A (es) |
| CN (2) | CN107922499B (es) |
| AR (1) | AR105938A1 (es) |
| AU (1) | AU2016319433A1 (es) |
| BR (1) | BR112018003494A2 (es) |
| CA (1) | CA2989993A1 (es) |
| CO (1) | CO2018000652A2 (es) |
| ES (1) | ES2846175T3 (es) |
| IL (2) | IL256519A (es) |
| MX (2) | MX377865B (es) |
| PE (1) | PE20181051A1 (es) |
| PH (1) | PH12018500290A1 (es) |
| RU (2) | RU2019128192A (es) |
| SG (1) | SG11201800127WA (es) |
| TW (1) | TW201716442A (es) |
| WO (1) | WO2017043466A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110769828A (zh) | 2017-05-12 | 2020-02-07 | 香港科技大学 | 作为epha4抑制剂的杂环化合物 |
| AU2018313028B2 (en) * | 2017-08-10 | 2023-05-25 | Grifols Diagnostic Solutions Inc. | Compositions, methods and/or kits comprising a recombinant human CD38-extracellular domain |
| US20220162564A1 (en) * | 2019-03-08 | 2022-05-26 | Kaneka Corporation | Mass culture of pluripotent stem cells |
| BR112021025161A2 (pt) * | 2019-07-01 | 2022-01-25 | Eisai R&D Man Co Ltd | Anticorpo anti-epha4 |
| CA3192342A1 (en) * | 2020-12-24 | 2022-06-30 | Eisai R&D Management Co., Ltd. | Anti-epha4 antibody |
| MX2023004848A (es) | 2020-12-24 | 2023-05-10 | Eisai R&D Man Co Ltd | Composicion farmaceutica terapeutica para tratar la esclerosis lateral amiotrofica. |
| TW202323286A (zh) * | 2021-11-11 | 2023-06-16 | 日商衛材R&D企管股份有限公司 | 抗EphA4抗體 |
| US20260022179A1 (en) * | 2021-11-22 | 2026-01-22 | China Medical University | Antibody mono-or multi-specific to ephrin type-a receptor 10, chimeric antigen receptor t-cell expressing the same and uses thereof |
| WO2023122647A2 (en) * | 2021-12-22 | 2023-06-29 | The University Of Chicago | Methods for detecting or treating influenza infections |
| WO2024047558A2 (en) * | 2022-08-31 | 2024-03-07 | Immuneel Therapeutics Private Limited | Antigen-binding proteins and chimeric antigen receptors specific for domain 9 of human cd307e |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4334271B2 (ja) * | 2003-05-07 | 2009-09-30 | セレスター・レキシコ・サイエンシズ株式会社 | 抗体配列作成装置、抗体配列作成方法、プログラム、および、記録媒体 |
| CA2528549A1 (en) * | 2003-06-06 | 2005-06-02 | Medimmune, Inc. | Use of epha4 and modulator of epha4 for diagnosis, treatment and prevention of cancer |
| DE602004031772D1 (de) * | 2003-12-04 | 2011-04-21 | Abbott Biotherapeutics Corp | Anti-ip-10-antikörper |
| JP2007525220A (ja) * | 2004-02-27 | 2007-09-06 | オンコセラピー・サイエンス株式会社 | Ｐｉｎ−ｐｒｃ移行遺伝子 |
| US20080008719A1 (en) * | 2004-07-10 | 2008-01-10 | Bowdish Katherine S | Methods and compositions for the treatment of prostate cancer |
| EP1662259A1 (en) | 2004-11-25 | 2006-05-31 | Cellzome Ag | Use of Eph receptor inhibitors for the treatment of neurodegenerative diseases |
| WO2007102383A1 (en) | 2006-02-28 | 2007-09-13 | Oncotherapy Science, Inc. | Methods for damaging cells using effector functions of anti-epha4 antibodies |
| US7910324B2 (en) | 2007-06-08 | 2011-03-22 | Eisai R&D Management Co., Ltd. | Method of screening for compounds which affect the processing of EphA4 by γ-secretase |
| WO2009069808A1 (ja) | 2007-11-30 | 2009-06-04 | Eisai R & D Management Co., Ltd. | 新規活性を有するEphA4ポリペプチドおよびその用途 |
| WO2010141974A1 (en) | 2009-06-10 | 2010-12-16 | The University Of Melbourne | Therapeutic applications |
| JP2010285413A (ja) * | 2009-06-10 | 2010-12-24 | Univ Of Melbourne | 治療用途 |
| PH12012500564A1 (en) * | 2009-10-09 | 2012-10-22 | Sanofi Sa | Polypeptides for binding to the receptor for advanced glycation endproducts as well as compositions and methods involving the same |
| WO2012081502A1 (ja) | 2010-12-17 | 2012-06-21 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ゼラチナーゼによるEphA4の切断反応を指標としたスクリーニング方法 |
| EP2703814B1 (en) * | 2011-04-25 | 2017-11-01 | Eisai R&D Management Co., Ltd. | Method for detecting neurological disease associated with cognitive dysfunction by measuring epha4 extracellular domain |
| GB201107996D0 (en) | 2011-05-13 | 2011-06-29 | Vib Vzw | EphA4 is a diease modifier in motor neuron disease |
| ES2925224T3 (es) * | 2014-07-31 | 2022-10-14 | Us Gov Health & Human Services | Anticuerpos monoclonales humanos contra EphA4 y su uso |
-
2016
- 2016-09-06 MX MX2018002164A patent/MX377865B/es unknown
- 2016-09-06 EP EP16844327.3A patent/EP3381941B1/en active Active
- 2016-09-06 ES ES16844327T patent/ES2846175T3/es active Active
- 2016-09-06 PE PE2017002724A patent/PE20181051A1/es not_active Application Discontinuation
- 2016-09-06 CN CN201680048438.4A patent/CN107922499B/zh not_active Expired - Fee Related
- 2016-09-06 CA CA2989993A patent/CA2989993A1/en not_active Abandoned
- 2016-09-06 CN CN202010179415.5A patent/CN111320693B/zh not_active Expired - Fee Related
- 2016-09-06 SG SG11201800127WA patent/SG11201800127WA/en unknown
- 2016-09-06 TW TW105128767A patent/TW201716442A/zh unknown
- 2016-09-06 AU AU2016319433A patent/AU2016319433A1/en not_active Abandoned
- 2016-09-06 WO PCT/JP2016/076102 patent/WO2017043466A1/ja not_active Ceased
- 2016-09-06 KR KR1020187004754A patent/KR20180041136A/ko not_active Withdrawn
- 2016-09-06 RU RU2019128192A patent/RU2019128192A/ru unknown
- 2016-09-06 BR BR112018003494-0A patent/BR112018003494A2/pt not_active Application Discontinuation
- 2016-09-06 US US15/753,611 patent/US10428140B2/en active Active
- 2016-09-06 RU RU2018106456A patent/RU2719158C2/ru active
- 2016-09-06 AR ARP160102725A patent/AR105938A1/es unknown
- 2016-09-06 JP JP2017539163A patent/JP6738814B2/ja active Active
-
2017
- 2017-12-24 IL IL256519A patent/IL256519A/en unknown
-
2018
- 2018-01-24 CO CONC2018/0000652A patent/CO2018000652A2/es unknown
- 2018-02-08 PH PH12018500290A patent/PH12018500290A1/en unknown
- 2018-02-20 MX MX2020002406A patent/MX2020002406A/es unknown
-
2019
- 2019-08-23 JP JP2019152823A patent/JP6770153B2/ja not_active Expired - Fee Related
- 2019-08-25 IL IL26888919A patent/IL268889A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR105938A1 (es) | Anticuerpo anti-epha4 | |
| CO2018004532A2 (es) | Anticuerpos anti-cd19 humano con alta afinidad | |
| AR111630A1 (es) | ANTICUERPOS ANTI-SIRPa | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| PE20211863A1 (es) | Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap | |
| AR109715A1 (es) | Anticuerpos anti-cd27 | |
| CO2018013500A2 (es) | Anticuerpos anti-pd-l1 y usos de los mismos | |
| CO2017005738A2 (es) | Anticuerpos anti-pd-1 | |
| AR096687A1 (es) | Anticuerpos anti-fcrh5 | |
| AR104250A1 (es) | Anticuerpo anti-notch4 humano | |
| MX2018007089A (es) | Moleculas biespecificas que tienen inmunorreactividad con pd-1 y ctla-4, y metodos de uso de las mismas. | |
| CL2013003373A1 (es) | Proteina de union al antigeno de maduración de linfocitos b (bcma); composicion farmacéutica que comprende la proteína; uso para preparar un medicamento util para tratar mieloma multiple o (mm) leucemia linfocitica cronica (cll). | |
| MD4716B1 (ro) | Anticorpi anti-LAG3 şi fragmente de legare a antigenului | |
| PE20181270A1 (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano | |
| NZ625403A (en) | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration | |
| EA201890305A1 (ru) | Гуманизированные или химерные cd3-антитела | |
| AR102594A1 (es) | ANTICUERPOS ANTI-IL-1b Y MÉTODOS DE USO | |
| AR096617A1 (es) | Anticuerpos anti-tweakr y sus usos | |
| NZ630610A (en) | Tau peptides, anti-tau antibodies, and methods of use thereof | |
| AR099855A1 (es) | Anticuerpos hemaglutinina del virus antiinfluenza b y métodos de uso | |
| PE20141547A1 (es) | Anticuerpos neutralizantes frente a las exotoxinas principales tcda y tcdb de clostridium difficile | |
| AR102592A1 (es) | Anticuerpos biespecíficos y métodos de uso en oftalmología | |
| PE20191076A1 (es) | Anticuerpo que se une especificamente a pd-1 y fragmento funcional del mismo | |
| PE20201171A1 (es) | Anticuerpos de cadena pesada que se unen a cd22 | |
| AR115192A1 (es) | Anticuerpos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |